Short Interest in SOPHiA GENETICS SA (NASDAQ:SOPH) Decreases By 34.0%

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) was the target of a significant drop in short interest in the month of January. As of January 31st, there was short interest totalling 19,800 shares, a drop of 34.0% from the January 15th total of 30,000 shares. Based on an average daily volume of 53,500 shares, the days-to-cover ratio is presently 0.4 days. Approximately 0.0% of the company's stock are sold short.

Institutional Investors Weigh In On SOPHiA GENETICS

A number of hedge funds and other institutional investors have recently modified their holdings of SOPH. Principal Financial Group Inc. increased its holdings in SOPHiA GENETICS by 6.3% in the third quarter. Principal Financial Group Inc. now owns 1,455,142 shares of the company's stock valued at $5,290,000 after buying an additional 86,764 shares during the last quarter. Green Alpha Advisors LLC increased its holdings in shares of SOPHiA GENETICS by 119.3% in the 4th quarter. Green Alpha Advisors LLC now owns 47,216 shares of the company's stock valued at $145,000 after acquiring an additional 25,686 shares during the last quarter. Silverberg Bernstein Capital Management LLC acquired a new stake in shares of SOPHiA GENETICS during the 4th quarter worth about $70,000. Federated Hermes Inc. lifted its stake in SOPHiA GENETICS by 40.5% during the fourth quarter. Federated Hermes Inc. now owns 100,000 shares of the company's stock worth $312,000 after purchasing an additional 28,819 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its holdings in SOPHiA GENETICS by 23.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 21,619 shares of the company's stock valued at $68,000 after purchasing an additional 4,115 shares in the last quarter. 31.59% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Craig Hallum began coverage on shares of SOPHiA GENETICS in a report on Wednesday, December 18th. They set a "buy" rating and a $11.00 target price on the stock. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, SOPHiA GENETICS currently has an average rating of "Moderate Buy" and an average target price of $7.40.

SOPHiA GENETICS Stock Up 11.2 %

Shares of SOPH stock traded up $0.45 during trading hours on Tuesday, reaching $4.46. 314,925 shares of the stock were exchanged, compared to its average volume of 96,684. SOPHiA GENETICS has a 12-month low of $2.70 and a 12-month high of $7.37. The business's fifty day moving average is $3.46 and its two-hundred day moving average is $3.54. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.80 and a quick ratio of 3.59. The firm has a market capitalization of $291.59 million, a P/E ratio of -4.09 and a beta of 1.03.

About SOPHiA GENETICS

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.